Compare Medtronic PLC (MDT) vs QXO Inc. Common Stock (QXO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs QXO Inc. Common Stock — how do they compare? Medtronic PLC trades at $95.09 (market cap $118.97B), while QXO Inc. Common Stock trades at $10.36 (market cap $11.43B). The key difference: Medtronic PLC is far larger — about 10.4× QXO Inc. Common Stock's market cap, and Medtronic PLC pays a 3.1% dividend while QXO Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and QXO Inc. Common Stock for 0 Days on average.
| MDT | QXO | |
|---|---|---|
Market Cap | $118.97B | $11.43B |
Volume | 24,932,018 | 21,645,941 |
Sector | Health | Industrials |
52-Week High | $105.35 | $27.07 |
52-Week Low | $73.75 | $10.33 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $138.31B | $16.75B |
Dividend Yield | 3.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $94.23, up 2.5% with strong technical momentum near resistance at $95. The stock shows solid fundamentals with consistent earnings beats, 13.93% net margins, and a 49-year dividend growth streak. Recent CPT code approvals for medical devices and raised 2026 guidance signal operational strength. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near-term.
MDT offers value with 3.2% dividend yield and 7%+ revenue growth, though debt levels have risen to 31.1% of assets. Analyst consensus remains strongly bullish (61% buy ratings) with $97.73 price target. Key risks include execution of the MiniMed separation and medical device competition. The stock presents a balanced opportunity for income and growth investors.
QXO trades at $11.02, up 3.57% on the day but down significantly year-to-date amid weak residential demand and integration challenges from its TopBuild acquisition. The stock shows neutral technical signals with support near $10-$11 and resistance at $12. Fundamentally, revenue grew to $6.84B in 2025 but net losses deepened to $279.4M, with a negative profit margin of -5.17% in 2026. Analyst sentiment remains bullish with a $22.89 consensus target, though recent news highlights margin pressure and execution risks.
The outlook hinges on successful integration of acquisitions and EBITDA growth targets, but high execution risk, negative earnings, and sector headwinds pose substantial downside. With 100% buy ratings from analysts and institutional accumulation, patient investors may see upside if management delivers on its playbook, though volatility is expected near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About QXO Inc. Common Stock
QXO, Inc. is a distributor of roofing, insulation, waterproofing, and other building materials, serving contractors and builders across US and Canada through its network of branch locations.
Read more on QXO →
